COGT Cogent Biosciences Inc
Price (delayed)
$5.72
Market cap
$651.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.94
Enterprise value
$570.52M
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed
Highlights
The company's debt fell by 7% YoY and by 2% QoQ
The EPS rose by 3% QoQ
The company's net income fell by 33% YoY and by 6% QoQ
Cogent Biosciences's quick ratio has decreased by 26% YoY and by 19% from the previous quarter
Key stats
What are the main financial stats of COGT
Market
Valuations
Earnings
Shares outstanding
113.85M
Market cap
$651.22M
Enterprise value
$570.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$275.94M
Net income
-$255.86M
EBIT
-$255.86M
EBITDA
-$251.51M
Free cash flow
-$208.36M
Per share
Balance sheet
Liquidity
EPS
-$1.94
EPS diluted
-$1.94
Free cash flow per share
-$2.01
Book value per share
$2.32
Revenue per share
$0
TBVPS
$3.16
Total assets
$327.9M
Total liabilities
$71.61M
Debt
$17.47M
Equity
$256.29M
Working capital
$240.76M
Debt to equity
0.07
Current ratio
5.32
Quick ratio
5.15
Net debt/EBITDA
0.32
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-63.3%
Return on equity
-74.9%
Return on invested capital
-101.8%
Return on capital employed
-94%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COGT stock price
How has the Cogent Biosciences stock price performed over time
Intraday
-1.21%
1 week
-11.59%
1 month
-24.04%
1 year
-15.26%
YTD
-26.67%
QTD
-4.51%
Financial performance
How have Cogent Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$275.94M
Net income
-$255.86M
Gross margin
N/A
Net margin
N/A
COGT's operating income is down by 33% year-on-year and by 6% since the previous quarter
The company's net income fell by 33% YoY and by 6% QoQ
Growth
What is Cogent Biosciences's growth rate over time
Valuation
What is Cogent Biosciences stock price valuation
P/E
N/A
P/B
2.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 3% QoQ
The P/B is 19% above the 5-year quarterly average of 2.1 but 7% below the last 4 quarters average of 2.7
The company's equity fell by 19% QoQ
Efficiency
How efficient is Cogent Biosciences business performance
COGT's return on invested capital is down by 11% since the previous quarter
The company's return on equity fell by 10% YoY and by 6% QoQ
The ROA has contracted by 9% YoY and by 4.8% from the previous quarter
Dividends
What is COGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COGT.
Financial health
How did Cogent Biosciences financials performed over time
The total liabilities rose by 29% year-on-year and by 3.3% since the previous quarter
Cogent Biosciences's quick ratio has decreased by 26% YoY and by 19% from the previous quarter
The company's debt is 93% lower than its equity
The company's equity fell by 19% QoQ
Cogent Biosciences's debt to equity has increased by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.